查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649494

抗凝血剂市场：预测（2025-2030 年）

Anticoagulants Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

抗凝血剂市场预计将从 2025 年的 411.71 亿美元成长到 2030 年的 713.12 亿美元，复合年增长率为 11.61%。

由于心血管疾病盛行率显着上升以及静脉血栓栓塞症和动脉血栓症病例数量的增加，预计抗凝血剂市场在整个预测期内将保持稳定成长。抗凝血剂是专门用于预防血栓的药物，尤其适用于高风险族群。血栓会阻塞血管，导致大脑、肺和心臟等重要器官无法获得足够的血液流向。这种阻塞可能导致严重的併发症，包括因缺氧而导致的器官损伤。此外，心房颤动等情况会导致血栓形成，从而导致心臟衰竭、中风和其他心臟相关问题。全球肥胖人数的增加进一步加剧了血栓相关心臟病的流行。此外，由于免疫力较弱和其他健康因素，老年人罹患血栓的风险更高。全球肥胖率的上升和老年人口的增加是预计未来几年推动抗凝血剂需求的主要因素。此外，这些药物通常在心血管手术中使用以防止血栓，随着全球此类手术数量的增加，市场成长预计也会增加。

抗凝血剂市场的关键驱动因素

  • 心臟病发病率不断上升：被诊断患有心臟病的患者数量不断增加是抗凝血剂市场发展的主要驱动力。根据世界卫生组织（WHO）的数据，心血管疾病（CVD）后果严重，每年约有1,790万人死于此类疾病，约占全球死亡人数的31%。吸烟、营养不良和缺乏运动等因素会增加心臟病和中风的发生率。在美国，心臟病仍然是第一大死因，其中以冠心病最为常见。肥胖人口的不断增长是心臟病发作的一个重要因素，随着医疗保健提供者专注于识别风险因素和实施有效的治疗方法，对抗凝剂的需求也随之增加。
  • 心臟病发作后的治疗：抗凝血剂对心臟病发作的患者特别有益，有助于降低后续事件的风险。例如，美国每年约有72.5万人心臟病发作，其中约30％会復发。这一趋势将对预测期内抗凝血剂市场的成长产生正面影响。

区域展望

  • 北美：全球抗凝血剂市场分为北美、南美、欧洲、中东和非洲以及亚太等地区。由于北美拥有先进的医疗保健基础设施和对该领域的持续投资，预计将占据该市场的大部分份额。心血管疾病发病率的上升和对创新治疗的重视程度的提高进一步推动了该地区的成长。
  • 亚太地区：受中国和印度等国家广泛的铁路网络的推动，该地区预计也将显着增长。政府旨在改善医疗保健服务的措施也将促进市场扩张。

总之，由于医疗保健投资的增加、需要抗凝血治疗的外科手术的增加、心血管疾病发生率的上升以及人口老化，抗凝血药物市场预计将成长。

为什么要购买这份报告？

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

5. 抗凝血药市场（依药物类别划分）

  • 介绍
  • 维生素 K 拮抗剂（香豆素抗凝血剂）
  • 低分子量肝素 (LMWH)
  • 直接口服抗凝血剂 (DOAC)
  • 其他的

第六章 抗凝血剂市场（依应用）

  • 介绍
  • 心房颤动
  • 心臟病发作
  • 深层静脉栓塞症
  • 肺动脉栓塞
  • 其他的

7. 抗凝血剂市场（按分销管道）

  • 介绍
  • 医院药房
  • 零售药局
  • 在线的

8. 抗凝血剂市场（按地区）

  • 介绍
  • 北美洲
    • 按药品类别
    • 按应用
    • 按分销管道
    • 按国家
  • 南美洲
    • 按药品类别
    • 按应用
    • 按分销管道
    • 按国家
  • 欧洲
    • 按药品类别
    • 按应用
    • 按分销管道
    • 按国家
  • 中东和非洲
    • 按药品类别
    • 按应用
    • 按分销管道
    • 按国家
  • 亚太地区
    • 按药品类别
    • 按应用
    • 按分销管道
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol Myers Squibb Company
  • Alexion Pharmaceuticals, Inc.
  • Daiichi Sankyo, Inc.
  • Anthos Therapeutics
  • AcelRx Pharmaceuticals, Inc.
简介目录
Product Code: KSI061613518

The anticoagulants market is projected to grow at a CAGR of 11.61%, from US$41.171 billion in 2025 to US$71.312 billion in 2030.

The anticoagulant market is expected to experience steady growth throughout the forecast period, driven by a significant rise in the prevalence of cardiovascular diseases, as well as an increase in cases of venous thromboembolism and arterial thrombosis. Anticoagulants are medications designed to prevent blood clots, particularly for individuals at high risk. These medications are crucial for those susceptible to clots, helping to reduce the likelihood of severe heart conditions such as heart attacks and strokes.Blood clots can obstruct blood vessels, preventing essential organs-including the brain, lungs, and heart-from receiving adequate blood flow. This obstruction can lead to serious complications, including organ damage due to lack of oxygen. Conditions like atrial fibrillation can also result in blood clot formation, leading to heart failure, strokes, and other heart-related issues. The global rise in obesity is further contributing to the prevalence of heart diseases associated with blood clots.Additionally, older adults are at a higher risk for clotting due to weakened immune systems and other health factors. The increasing rates of obesity and the growing global geriatric population are key drivers anticipated to boost demand for anticoagulant medications in the coming years. Furthermore, these drugs are commonly administered during heart surgeries to prevent clot formation, which is expected to further enhance market growth as the number of such procedures rises globally.

Key Drivers of the Anticoagulants Market

  • Increasing Prevalence of Heart Diseases: The rising number of individuals diagnosed with heart disease is a primary driver for the anticoagulant market. Cardiovascular diseases (CVDs) have severe consequences; according to the World Health Organization (WHO), approximately 17.9 million people die from these diseases annually, accounting for about 31% of all global deaths. Factors such as smoking, poor nutrition, and lack of physical activity have contributed to higher rates of heart attacks and strokes. In the United States, heart disease remains the leading cause of death, with coronary heart disease being the most common type. The growing obese population is a significant contributor to heart attacks, driving demand for anticoagulants as healthcare providers focus on identifying risk factors and implementing effective treatments.
  • Post-Heart Attack Treatment: Anticoagulants are particularly beneficial for patients who have experienced a heart attack, as they help reduce the risk of subsequent events. For instance, approximately 725,000 people in the U.S. suffer a heart attack each year, with around 30% being repeat cases. This trend positively impacts the growth of the anticoagulant market during the forecast period.

Geographical Outlook

  • North America: The global anticoagulant market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is projected to hold a significant share of this market due to its advanced healthcare infrastructure and ongoing investments in this sector. The region's growth is further supported by increasing incidences of cardiovascular diseases and a strong emphasis on innovative treatments.
  • Asia Pacific: This region is also expected to witness substantial growth driven by extensive rail networks in countries like China and India. Government initiatives aimed at improving healthcare access will also contribute to market expansion.

In summary, the anticoagulant market is poised for growth driven by rising rates of cardiovascular diseases and an aging population alongside increased healthcare investments and surgical procedures requiring anticoagulation therapy.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The anticoagulants market is segmented and analyzed as below:

By Drug Class

  • Vitamin K antagonists (coumarin anticoagulants)
  • Low molecular weight heparins (LMWH)
  • Direct Oral Anticoagulants (DOACs)
  • Others

By Application

  • Atrial Fibrillation
  • Heart Attacks
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ANTICOAGULANTS MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Vitamin K antagonists (coumarin anticoagulants)
  • 5.3. Low molecular weight heparins (LMWH)
  • 5.4. Direct Oral Anticoagulants (DOACs)
  • 5.5. Others

6. ANTICOAGULANTS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Atrial Fibrillation
  • 6.3. Heart Attacks
  • 6.4. Deep Vein Thrombosis
  • 6.5. Pulmonary Embolism
  • 6.6. Others

7. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online

8. ANTICOAGULANTS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. UK
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Aspen Holdings
  • 10.2. Bayer AG
  • 10.3. Boehringer Ingelheim International GmbH
  • 10.4. Pfizer Inc.
  • 10.5. Johnson & Johnson Services, Inc.
  • 10.6. Bristol Myers Squibb Company
  • 10.7. Alexion Pharmaceuticals, Inc.
  • 10.8. Daiichi Sankyo, Inc.
  • 10.9. Anthos Therapeutics
  • 10.10. AcelRx Pharmaceuticals, Inc.